| Phase II trial of temozolomide in patients with progressive low-grade glioma JA Quinn, DA Reardon, AH Friedman, JN Rich, JH Sampson, ... Journal of clinical oncology 21 (4), 646-651, 2003 | 318 | 2003 |
| Neutrophil migration is defective during recombinant human granulocyte-macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in humans WP Peters, A Stuart, ML Affronti, CS Kim, RE Coleman | 159 | 1988 |
| Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy ML Affronti, CR Heery, JE Herndon, JN Rich, DA Reardon, A Desjardins, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2009 | 154 | 2009 |
| Interstitial chemotherapy with biodegradable BCNU (Gliadel®) wafers in the treatment of malignant gliomas DA Bota, A Desjardins, JA Quinn, ML Affronti, HS Friedman Therapeutics and clinical risk management 3 (5), 707-715, 2007 | 146 | 2007 |
| 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow … EJ Shpall, RB Jones, RC Bast Jr, GL Rosner, R Vandermark, M Ross, ... Journal of clinical oncology 9 (1), 85-93, 1991 | 102 | 1991 |
| Phase I study of Gliadel™ wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas S Gururangan, I Cokgor, JN Rich, S Edwards, ML Affronti, JA Quinn, ... Neuro-oncology 3 (4), 246-250, 2001 | 96 | 2001 |
| Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study L Cartee, WP Petros, GL Rosner, C Gilbert, S Moore, ML Affronti, JA Hoke, ... Cytokine 7 (5), 471-477, 1995 | 79 | 1995 |
| Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses R Clark-Snow, ML Affronti, CN Rittenberg Supportive Care in Cancer 26, 557-564, 2018 | 76 | 2018 |
| Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem … DA Rizzieri, JJ Vredenburgh, R Jones, M Ross, EJ Shpall, A Hussein, ... Journal of clinical oncology 17 (10), 3064-3074, 1999 | 72 | 1999 |
| AFM induction chemotherapy followed by intensive alkylating agent consolidation with autologous bone marrow support (ABMS) for advanced breast cancer: current results RB Jones, EJ Shpall, M Ross, R Bast, M Affronti, WP Peters Proc Am Soc Clin Oncol 9 (9), 1990 | 67 | 1990 |
| The duke afm program intensive induction chemotherapy for metastatic breast cancer RB Jones, EJ Shpall, J Shogan, ML Affronti, D Coniglio, L Hart, E Halperin, ... Cancer 66 (3), 431-436, 1990 | 65 | 1990 |
| Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma DA Reardon, JA Quinn, JN Rich, S Gururangan, J Vredenburgh, ... Neuro-oncology 6 (2), 134-144, 2004 | 53 | 2004 |
| GM-CSF primed peripheral blood progenitor cells (PBPC) coupled with autologous bone marrow transplantation (ABMT) will eliminate absolute leukopenia following high dose … WP Peters, J Kurtzberg, G Kirkpatrick, S Atwater, C Gilbert, M Borowitz, ... Blood 74 (suppl 1), 50, 1989 | 52 | 1989 |
| A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation … JJ Vredenburgh, B Madan, D Coniglio, M Ross, G Broadwater, ... Bone marrow transplantation 37 (11), 1009-1015, 2006 | 42 | 2006 |
| Improved survival with consolidation high-dose cyclophosphamide, cisplatin and carmustine (HD-CPB) compared with observation in women with metastatic breast cancer (MBC) and … B Madan, G Broadwater, P Rubin, J Edwards, G Long, NC Chao, ... Proc Am Soc Clin Oncol 19 (48a), 2000 | 42 | 2000 |
| Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice ML Affronti, SM Schneider, JE Herndon, S Schlundt, HS Friedman Supportive Care in Cancer 22, 1897-1905, 2014 | 41 | 2014 |
| Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic … JJ Vredenburgh, D Coniglio, G Broadwater, RB Jones, M Ross, EJ Shpall, ... Biology of Blood and Marrow Transplantation 12 (2), 195-203, 2006 | 37 | 2006 |
| A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood … AM Hussein, WP Petros, M Ross, JJ Vredenburgh, ML Affronti, RB Jones, ... Cancer chemotherapy and pharmacology 37, 561-568, 1996 | 34 | 1996 |
| Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab in subjects with recurrent malignant glioma ML Affronti, JG Jackman, F McSherry, JE Herndon, EC Massey Jr, E Lipp, ... The oncologist 23 (8), 889-e98, 2018 | 31 | 2018 |
| A cross sectional analysis from a single institution’s experience of psychosocial distress and health-related quality of life in the primary brain tumor population DM Randazzo, F McSherry, JE Herndon, ML Affronti, ES Lipp, C Flahiff, ... Journal of Neuro-oncology 134, 363-369, 2017 | 30 | 2017 |
Jeremy N. RichUniversity of PittsburghVerified email at upmc.edu
